Fixed duration Calquence based regimens recommended for EMA Committee for chronic lymphocytic leukaemia: AstraZenaca Ruchika Sharma30 April 2025 1:30 PM ISTAstraZeneca has announced that a fixed-duration regimen of Calquence (acalabrutinib) in combination with venetoclax, with or without...
Roche Gazyva application accepted by USFDA for lupus nephritis Ruchika Sharma5 March 2025 1:45 PM ISTGazyva/Gazyvaro is an anti-CD20 monoclonal antibody in a randomised phase III study to demonstrate a CRR benefit in lupus nephritis.
Venetoclax-obinutuzumab combo bests chemoimmunotherapy among chronic lymphocytic leukemia patients Jacinthlyn Sylvia15 May 2023 9:00 AM ISTIn healthy people with chronic lymphocytic leukemia (CLL), venetoclax-obinutuzumab with or without ibrutinib was better than chemoimmunotherapy, says...
AstraZeneca Calquence gets Japenese nod for treatment-naïve chronic lymphocytic leukaemia Ruchika Sharma1 Jan 2023 10:00 AM ISTCalquence (acalabrutinib) is a next-generation, selective inhibitor of BTK.
Three-drug combination therapy effective in patients with high-risk CLL, trial shows Dr. Kamal Kant Kohli12 Dec 2022 6:00 AM ISTResearchers have found in a phase 2 clinical trial led by Dana-Farber Cancer Institute that three-drug combination that sent chronic lymphocytic...
Acalabrutinib, venetoclax and obinutuzumab as frontline therapy for chronic lymphocytic leukemia: Lancet MD Editorial Team24 Sept 2021 9:00 PM ISTUSA: In a trial led by Matthew S Davids, individuals with undiscovered minimum residual disease (MRD) and untreated chronic lymphocytic leukemia who...
